Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
user
  1. Dashboard
  2. My Profile
  3. My Address
  4. My Orders
  5. Acro Membership
Login Register
Promotion
Recombinant Proteins ClearClear history
Recombinant Proteins CloseClose
Browse Products By Molecule Name a-zA-Z
TL1A Hot |GMP Cytokines Hot |Streptavidin（SA） Hot |Claudin 18.2 |Cadherin-17 
0
There is no goods in the shopping cart !
My Cart|Secure Checkout
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > IL-2 R alpha

IL-2 R alpha

Brief Information

Name:Interleukin-2 receptor alpha chain
Target Synonym:TAC antigen,p55,IL2-RA,Interleukin-2 receptor subunit alpha,IL-2-RA,IL-2R subunit alpha,IL2RA,Interleukin 2 Receptor Subunit Alpha,Interleukin 2 Receptor, Alpha,IL-2 Receptor Subunit Alpha,Insulin-Dependent Diabetes Mellitus 10,CD25 Antigen,IDDM10,IMD41,TCGFR,CD25,Interleukin-2 Receptor alpha Subunit,IL-2R alpha
Number of Launched Drugs:3
Number of Drugs in Clinical Trials:16
Lastest Research Phase:Approved

Antibody Licensing

Project Name Project Stage Molecule Type Host Species Therapeutic Area Indications
CD25 mAb - 01 PCC Solid Tumor Solid tumor

Product ListCompare or Buy

Product> Filter Results
By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
ILA-C52H8 Cynomolgus Cynomolgus IL-2 R alpha / CD25 Protein, His Tag (MALS verified)
ILA-C52H8-structure
ILA-C52H8-sds
ILA-H82F9 Human Biotinylated Human IL-2 R alpha / CD25 Protein, Fc,Avitag™ (MALS verified)
ILA-H82F9-structure
ILA-H82F9-sds
ILA-C52H4 Canine Canine IL-2 R alpha / CD25 Protein, His Tag
ILA-C52H4-structure
ILA-C52H4-sds
ILA-M52H9 Mouse Mouse IL-2 R alpha / CD25 Protein, His Tag
ILA-M52H9-structure
ILA-M52H9-sds
ILA-H82E6 Human Biotinylated Human IL-2 R alpha / CD25 Protein, His,Avitag™, premium grade
ILA-H82E6-structure
ILA-H82E6-sds
ILA-H52H9 Human Human IL-2 R alpha / CD25 Protein, His Tag
ILA-H52H9-structure
ILA-H52H9-sds
ILA-H5251 Human Human IL-2 R alpha / CD25 Protein, Fc Tag (MALS verified)
ILA-H5251-structure
ILA-H5251-sds
ACRO Quality

Part of Bioactivity data

ILA-H82E6-Cell-based assay
IL-2 R alpha CELL

Biotinylated Human IL-2 R alpha, His,Avitag, premium grade (Cat. No. ILA-H82E6) inhibits the IL-2-dependent proliferation of Mo7e cells. The EC50 for this effect is 0.57-0.81 µg/mL (Routinely tested).

Protocol
ILA-H52H9-Cell-based assay
IL-2 R alpha CELL

Human IL-2 R alpha, His Tag (Cat. No. ILA-H52H9) inhibits the IL-2 dependent proliferation of Mo7e cells. The EC50 for this effect is 0.35-0.77 µg/mL (Routinely tested).

Protocol
ILA-H52H9-SPR
IL-2 R alpha SPR

Human IL-2 R alpha, His Tag (Cat. No. ILA-H52H9) captured on CM5 chip via anti-His antibody, can bind Human IL-2, Tag Free with an affinity constant of 29.9 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

Protocol
ILA-H5251-SPR
IL-2 R alpha SPR

Human IL-2 R alpha Protein, Fc Tag (Cat. No. ILA-H5251) captured on CM5 chip via anti-human IgG Fc antibody can bind Human IL-2, Tag Free with an affinity constant of 10.1 nM as determined in a SPR assay (Biacore T200) (Routinely tested)

Protocol

Customer Reviews

Synonym Name

IL2RA,CD25,p55,IL2-RA,IL-2-RA

Background

Interleukin-2 receptor subunit alpha (IL2RA) is also known as IL-2R subunit alpha, IL-2-RA, IL2-RA, TAC antigen, p55, CD antigen CD25, is a type I transmembrane glycoprotein. IL2RA is expressed on activated T cells and regulatory T cells, and is capable of binding IL2 with low affinity by itself. However, a ligand-induced high affinity heterotrimeric receptor complex is produced when IL2RA is associated non-covelently with the IL2 receptor beta and gamma chain, and subsequently initiates the intacellular signal pathways such as MAPK or JAK/STAT. On dendritic cells (DC), CD25 has been previously regarded as an activation marker, while both murine and human DC can express CD25, they do not express the beta-chain of the IL-2 receptor, which is indispensable for the execution of IL-2 signaling.

Clinical and Translational Updates

Related Molecule

IL-2

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Daclizumab biosimilar (Shanghai CP Guojian) Approved Shanghai Cp Guojian Pharmaceutical Co Ltd 健尼哌 Mainland China Rejection of renal transplantation null 2011-01-12 Rejection of renal transplantation Details
Basiliximab CHT-25; chRFT5; CHI-621; SDZ-CHI-621 Approved Novartis Pharma Ag 舒莱, Simulect Japan Rejection of organ transplantation Novartis Pharma Ag 1998-05-12 Anemia, Aplastic; Leukemia, Lymphocytic, Chronic, B-Cell; Kidney Failure, Chronic; Uveitis; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Emphysema; Pulmonary Disease, Chronic Obstructive; Colitis, Ulcerative; Primary Myelofibrosis; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Rejection of renal transplantation; Multiple Myeloma; Rejection of organ transplantation; Hodgkin Disease; Coronavirus Disease 2019 (COVID-19); Myelodysplastic Syndromes; Keratoplasty rejection; Hemoglobinuria, Paroxysmal; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Cytokine Release Syndrome Details
Daclizumab R-35; BIIB-019; RO-247375 Approved Abbvie Inc, Biogen Inc, F. Hoffmann-La Roche Ltd Zinbryta, Zenapax United States Multiple Sclerosis Biogen Inc 1997-12-10 Retinal Diseases; Leukemia, T-Cell; Behcet Syndrome; Melanoma; Iritis; Thrombocytopenia; Uveitis; Rejection in heart transplantation; Lymphoma; Uveitis, Anterior; Colitis, Ulcerative; Asthma; Breast Neoplasms; Psoriasis; Multiple Sclerosis, Relapsing-Remitting; Arthritis, Juvenile; Radiation Injuries; Carcinoma, Ductal; Rejection of organ transplantation; Multiple Sclerosis; Myelodysplastic Syndromes; HTLV-I Infections; Gastrointestinal Diseases; Inflammatory Bowel Diseases; Granulomatosis with Polyangiitis; Diabetes Mellitus, Type 1; Leukemia; HIV Infections Details
Daclizumab biosimilar (Shanghai CP Guojian) Approved Shanghai Cp Guojian Pharmaceutical Co Ltd 健尼哌 Mainland China Rejection of renal transplantation null 2011-01-12 Rejection of renal transplantation Details
Basiliximab CHT-25; chRFT5; CHI-621; SDZ-CHI-621 Approved Novartis Pharma Ag 舒莱, Simulect Japan Rejection of organ transplantation Novartis Pharma Ag 1998-05-12 Anemia, Aplastic; Leukemia, Lymphocytic, Chronic, B-Cell; Kidney Failure, Chronic; Uveitis; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Emphysema; Pulmonary Disease, Chronic Obstructive; Colitis, Ulcerative; Primary Myelofibrosis; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Rejection of renal transplantation; Multiple Myeloma; Rejection of organ transplantation; Hodgkin Disease; Coronavirus Disease 2019 (COVID-19); Myelodysplastic Syndromes; Keratoplasty rejection; Hemoglobinuria, Paroxysmal; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Cytokine Release Syndrome Details
Daclizumab R-35; BIIB-019; RO-247375 Approved Abbvie Inc, Biogen Inc, F. Hoffmann-La Roche Ltd Zinbryta, Zenapax United States Multiple Sclerosis Biogen Inc 1997-12-10 Retinal Diseases; Leukemia, T-Cell; Behcet Syndrome; Melanoma; Iritis; Thrombocytopenia; Uveitis; Rejection in heart transplantation; Lymphoma; Uveitis, Anterior; Colitis, Ulcerative; Asthma; Breast Neoplasms; Psoriasis; Multiple Sclerosis, Relapsing-Remitting; Arthritis, Juvenile; Radiation Injuries; Carcinoma, Ductal; Rejection of organ transplantation; Multiple Sclerosis; Myelodysplastic Syndromes; HTLV-I Infections; Gastrointestinal Diseases; Inflammatory Bowel Diseases; Granulomatosis with Polyangiitis; Diabetes Mellitus, Type 1; Leukemia; HIV Infections Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Basiliximab biobetter (Mabtech/Sorrento) STI-003 Phase 3 Clinical Taizhou Maibo Taike Biotechnology Co Ltd Autoimmune Diseases Details
MDNA-11 MDNA-11; MDNA11 Phase 2 Clinical Medicenna Therapeutics Corp Solid tumours Details
RM-1995 RM-1995 Rakuten Medical Inc Squamous Cell Carcinoma of Head and Neck; Carcinoma, Squamous Cell Details
Inolimomab B-B10; BT-563; MAb-BT-563 Eusa Pharma, Jazz Pharmaceuticals Plc Details
Anti-interleukin-2 receptor monoclonal antibody Mikbeta1 HuMikβ1-1 Phase 1 Clinical F. Hoffmann-La Roche Ltd, National Institutes Of Health Leukemia; Leukemia, Lymphoid; Celiac Disease; Paraparesis, Tropical Spastic; Leukemia, Large Granular Lymphocytic Details
LMB-2 LMB-2; LMB-2a Phase 2 Clinical National Cancer Institute Leukemia; Leukemia, Hairy Cell; Skin Neoplasms; Myelodysplastic Syndromes; Myeloproliferative Disorders; Leukemia-Lymphoma, Adult T-Cell; Lymphoma; Melanoma; Myelodysplastic-Myeloproliferative Diseases Details
90Y Basiliximab Phase 2 Clinical City Of Hope National Medical Center Lymphoma, T-Cell, Peripheral; Hodgkin Disease; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute; Lymphoma, T-Cell, Cutaneous; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell Details
In 111-DOTA-Basiliximab Phase 1 Clinical City Of Hope National Medical Center Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute Details
RO-7296682 RO-7296682; RG-6292 Phase 1 Clinical F. Hoffmann-La Roche Ltd Solid tumours; Neoplasms Details
Nemvaleukin alfa RDB-1450; RDB-1419; ALKS-4230 Phase 3 Clinical Alkermes Plc Solid tumours; Ovarian Neoplasms; Skin Melanoma; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Melanoma Details
PT-101 PT-101; MK-6194 Phase 1 Clinical Pandion Therapeutics Colitis, Ulcerative; Dermatitis, Atopic Details
XmAb-564 XmAb-564; XmAb-27564 Phase 1 Clinical Xencor Inc Autoimmune Diseases Details
BA-1106 TS-1904; BA-1106; RR-102 Phase 1 Clinical Shandong Boan Biotechnology Co Ltd Solid tumours Details
Camidanlumab tesirine ADCT-301 Phase 2 Clinical Genmab A/S, Adc Therapeutics Sa Myelodysplastic Syndromes; Melanoma; Carcinoma, Non-Small-Cell Lung; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute; Fallopian Tube Neoplasms; Colorectal Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Urinary Bladder Neoplasms; Myeloproliferative Disorders; Solid tumours; Hodgkin Disease; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Stomach Neoplasms; Esophageal Neoplasms; Ovarian Neoplasms Details
Basiliximab biobetter (Mabtech/Sorrento) STI-003 Phase 3 Clinical Taizhou Maibo Taike Biotechnology Co Ltd Autoimmune Diseases Details
MDNA-11 MDNA-11; MDNA11 Phase 2 Clinical Medicenna Therapeutics Corp Solid tumours Details
RM-1995 RM-1995 Rakuten Medical Inc Squamous Cell Carcinoma of Head and Neck; Carcinoma, Squamous Cell Details
Inolimomab B-B10; BT-563; MAb-BT-563 Eusa Pharma, Jazz Pharmaceuticals Plc Details
Anti-interleukin-2 receptor monoclonal antibody Mikbeta1 HuMikβ1-1 Phase 1 Clinical F. Hoffmann-La Roche Ltd, National Institutes Of Health Leukemia; Leukemia, Lymphoid; Celiac Disease; Paraparesis, Tropical Spastic; Leukemia, Large Granular Lymphocytic Details
LMB-2 LMB-2; LMB-2a Phase 2 Clinical National Cancer Institute Leukemia; Leukemia, Hairy Cell; Skin Neoplasms; Myelodysplastic Syndromes; Myeloproliferative Disorders; Leukemia-Lymphoma, Adult T-Cell; Lymphoma; Melanoma; Myelodysplastic-Myeloproliferative Diseases Details
90Y Basiliximab Phase 2 Clinical City Of Hope National Medical Center Lymphoma, T-Cell, Peripheral; Hodgkin Disease; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute; Lymphoma, T-Cell, Cutaneous; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell Details
In 111-DOTA-Basiliximab Phase 1 Clinical City Of Hope National Medical Center Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute Details
RO-7296682 RO-7296682; RG-6292 Phase 1 Clinical F. Hoffmann-La Roche Ltd Solid tumours; Neoplasms Details
Nemvaleukin alfa RDB-1450; RDB-1419; ALKS-4230 Phase 3 Clinical Alkermes Plc Solid tumours; Ovarian Neoplasms; Skin Melanoma; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Melanoma Details
PT-101 PT-101; MK-6194 Phase 1 Clinical Pandion Therapeutics Colitis, Ulcerative; Dermatitis, Atopic Details
XmAb-564 XmAb-564; XmAb-27564 Phase 1 Clinical Xencor Inc Autoimmune Diseases Details
BA-1106 TS-1904; BA-1106; RR-102 Phase 1 Clinical Shandong Boan Biotechnology Co Ltd Solid tumours Details
Camidanlumab tesirine ADCT-301 Phase 2 Clinical Genmab A/S, Adc Therapeutics Sa Myelodysplastic Syndromes; Melanoma; Carcinoma, Non-Small-Cell Lung; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute; Fallopian Tube Neoplasms; Colorectal Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Urinary Bladder Neoplasms; Myeloproliferative Disorders; Solid tumours; Hodgkin Disease; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Stomach Neoplasms; Esophageal Neoplasms; Ovarian Neoplasms Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Email
Email
order@acrobiosystems.com
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA
linkedin twitter facebook youtube

Leave a message

Copyright © 2017 ACROBiosystems. All Rights Reserved
|Related Links|Privacy Policy|Terms and Conditions|Legal|Sitemap